Beyond Happy Accidents: Embracing The Complexity Of Precision Medicine

The Precision Medicine Initiative was launched in 2015 in the United States. And while this new paradigm was quick to be accepted by the healthcare industry, the true definition of precision medicine’s role in treatment and diagnosis is still in progress.

Described by then President Obama as “the right treatments at the right time, every time, to the right person,” today’s precision medicine is most commonly referred to as the development of specific patient care plans through the leveraging of pharmacogenomics – combining pharmacology and genomics to create medications that are customized to an individual’s genetic makeup.¹ Noted Hematologist, Dr. Robert S. Negrin, Professor of Medicine and former Chief of the Division of Blood and Marrow Transplantation at Stanford University, and Biorasi Scientific Advisory Board member, has a different take.

To learn more about Biorasi, visit their Clinical Leader page.